Sent to MediPurpose's shareholders earlier this week, the letter is published on the company's Website and is also available for download.
Written by MediPurpose's founder and CEO Patrick Yi, the letter summarizes key achievements and activities for the company's various business segments and corporate units in FY 2012:
● Blood Collection & Analytics (which includes SurgiLance(tm)
● Advanced Wound Care (which includes MediPlus(tm)
● New Business Development
● Corporate Organization
● Inbound Marketing
● Operations (which includes Medical Device Innovation and Medical Product Distribution)
Yi is optimistic about his company's continued success. "In a word, MediPurpose's future is very bright," said Yi. "With an expanded product portfolio, new members joining an already talented and motivated team, and the discipline developed through the adoption of best practices, MediPurpose is well positioned to continue striving for sales growth and increased profitability."
For more information about MediPurpose's medical products -- including pricing and no-cost product sample requests -- please visit http://www.medipurpose.com/
Founded in 1999, MediPurpose is a leading medical device company headquartered in Singapore, with offices in the United States and Europe.
Known for its popular babyLance(tm)
MediPurpose's Medical Device Innovation division offers angel funding and developmental expertise for new medical device inventors and innovative medical product companies that seek entrance into new medical device markets.
For more information about MediPurpose's medical products and solutions for inventors, innovators, manufacturers and distributors, please visit http://www.medipurpose.com.